Backgound/Aims: This study was performed to identify response predictors for Interferon therapy given to patients with chronic hepatitis C. Materials and Methods: The biochemical measures of liver injury that characterize viral hepatitis due to hepatitis C were followed prospectively in 84 individuals treated with α-Interferon. In addition, the liver histology and the hepatic iron content of these same individuals, prior to the initiation of Interferon therapy, were determined. Results: Patients not responding to the interferon therapy showed an increase in liver iron content from an average of 337 ug/g wet weight. In responder to a value of 1075 μg/g wet weight in non responders. γ-glutamyl transpeptidase levels in responders were significantly lower than in partial or non-responders. Conclusions: Both the hepatic iron content of the liver and the γ-glutamyl transpeptidase value prior to treatment were able to predict a clinical response to Interferon therapy. More importantly, the γ-glutamyl transpeptidase level measured in serum could be used to monitor the IFN response during treatment and was found to predict clinical exacerbations of hepatitis following withdrawal of interferon therapy.

Van Thiel, D., Friedlander, L., Malloy, P., Wright, H., Gurakar, A., Fagiuoli, S., et al. (1995). gamma-Glutamyl transpeptidase as a response predictor when using alpha-interferon to treat hepatitis C. HEPATO-GASTROENTEROLOGY, 42(6), 888-892.

gamma-Glutamyl transpeptidase as a response predictor when using alpha-interferon to treat hepatitis C

Fagiuoli S;
1995

Abstract

Backgound/Aims: This study was performed to identify response predictors for Interferon therapy given to patients with chronic hepatitis C. Materials and Methods: The biochemical measures of liver injury that characterize viral hepatitis due to hepatitis C were followed prospectively in 84 individuals treated with α-Interferon. In addition, the liver histology and the hepatic iron content of these same individuals, prior to the initiation of Interferon therapy, were determined. Results: Patients not responding to the interferon therapy showed an increase in liver iron content from an average of 337 ug/g wet weight. In responder to a value of 1075 μg/g wet weight in non responders. γ-glutamyl transpeptidase levels in responders were significantly lower than in partial or non-responders. Conclusions: Both the hepatic iron content of the liver and the γ-glutamyl transpeptidase value prior to treatment were able to predict a clinical response to Interferon therapy. More importantly, the γ-glutamyl transpeptidase level measured in serum could be used to monitor the IFN response during treatment and was found to predict clinical exacerbations of hepatitis following withdrawal of interferon therapy.
Articolo in rivista - Articolo scientifico
gamma-Glutamyl transpeptidase; response predictor; alpha-interferon; hepatitis C;
English
888
892
5
Van Thiel, D., Friedlander, L., Malloy, P., Wright, H., Gurakar, A., Fagiuoli, S., et al. (1995). gamma-Glutamyl transpeptidase as a response predictor when using alpha-interferon to treat hepatitis C. HEPATO-GASTROENTEROLOGY, 42(6), 888-892.
Van Thiel, D; Friedlander, L; Malloy, P; Wright, H; Gurakar, A; Fagiuoli, S; Irish, W
File in questo prodotto:
File Dimensione Formato  
Van Thiel DH (1995) Gamma-glutamyl transpeptidase as a response predictor when using alpha interferon to treat hepatitis C.pdf

Solo gestori archivio

Dimensione 2.74 MB
Formato Adobe PDF
2.74 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/353727
Citazioni
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 14
Social impact